Generate Biomedicines is trading $16.63 (+5.32%) on September 2, 2026, after H.C. Wainwright raised its price target to $30 from $25 while maintaining a Buy rating.
- The move extends the previous session’s gain.
- Early GB-0895 asthma data showed durable biomarker suppression, supporting less-frequent dosing.
- The company-specific catalyst is outweighing mixed broader-market conditions.